Moving forward, perhaps no recent development in the use of RT in metastatic prostate cancer has captured greater attention than the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).
Kristopher Dennis, MD, FRCPC
Advertisement
Articles by Kristopher Dennis, MD, FRCPC
Patients with advanced progressive cancer require care plans that address their physical, emotional, and psychosocial needs, as well as their goals of care.
Advertisement
Latest Updated Articles
- Palliative Care and Oncology: Integration Leads to Better Care
November 30th 2011
Advertisement
Advertisement
Trending on CancerNetwork
1
Atirmociclib/Fulvestrant Improves PFS in HR+/HER2– Breast Cancer
2
FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer
3
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
4
Which Novel Drug Classes Hold Promise in Multiple Myeloma Therapy?
5